Results 81 to 90 of about 22,483 (254)

Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria

PharmacoEconomics (Auckland), 2020
Background Paroxysmal nocturnal hemoglobinuria, characterized by intravascular hemolysis and venous thrombosis, can be managed with eculizumab, an inhibitor of the complement system; however, patients may periodically experience breakthrough hemolysis ...
Thomas O’Connell, M. Buessing, Scott J Johnson, L. Tu, Simu K. Thomas, I. Tomazos   +5 more
semanticscholar   +1 more source

Investigation of association between serum C‐reactive protein concentrations and proteinuria in dogs

Journal of Small Animal Practice, EarlyView.
Objectives Identify if serum C‐reactive protein concentrations and specific diseases are associated with proteinuria (defined as urine protein:creatinine ratio >0.2) in dogs without known pathological pre‐renal, renal or post‐renal causes. Materials and Methods Hypothesis generating retrospective study.
E. Ruane, M. M. A. Rodgers, C. H. Z. Hare, K. E. McCallum, T. L. Williams   +4 more
wiley   +1 more source

Paroxysmal nocturnal hemoglobinuria

Current Opinion in Hematology, 2012
The aim is to report on recent observations related to the natural history of paroxysmal nocturnal hemoglobinuria (PNH) and to review new therapeutic strategies for controlling the hemolysis of PNH.This review focuses on studies designed to characterize the long-term outcome of patients with PNH treated with eculizumab and to define the relationship ...
openaire   +7 more sources

Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease

Journal of Managed Care & Specialty Pharmacy, 2020
Patients with paroxysmal nocturnal hemoglobinuria (PNH) often experience a lengthy path to diagnosis. Fewer than 40% of patients with PNH receive a diagnosis within 12 months of symptom onset, and 24% of all PNH diagnoses can take 5 years or longer ...
M. Bektas, C. Copley-Merriman, Shahnaz Khan, S. Sarda, J. Shammo   +4 more
semanticscholar   +1 more source

Patient‐Reported Oral Symptoms and Their Impact on Well‐Being After Haematopoietic Cell Transplantation

Oral Diseases, EarlyView.
ABSTRACT Objective Oral complications may negatively influence outcomes of haematopoietic cell transplantation (HCT). A comprehensive view of oral symptoms and symptom burden post‐HCT is lacking. This study aimed to determine the prevalence, severity, and temporal relationships of oral symptoms and their impact on well‐being in the early post‐HCT phase.
Kristina Skallsjö, Michael T. Brennan, Bengt Hasséus, Jenny Öhman, Judith E. Raber‐Durlacher, Marie‐Charlotte D. N. J. M. Huysmans, Alexa M. G. A. Laheij, Stephanie J. M. van Leeuwen, Allan J. Hovan, Karin Garming Legert, Scott Isom, David M. Kline, Nicole M. A. Blijlevens, Jan‐Erik Johansson, Inger von Bültzingslöwen   +14 more
wiley   +1 more source

Anemia hemolítica causada por Ditaxis desertorum (Euphorbiaceae) em bovinos [PDF]

Pesquisa Veterinária Brasileira, 1997
Ditaxis desertorum Pax et K. Hoffm., planta herbácea da família Euphorbiaceae, causou experimentalmente em bovinos um quadro caracterizado por hemoglobinúria em virtude de sua ação hemolítica, quando administrada por via oral em doses diárias de 1,0 a 2 ...
Carlos Hubinger Tokarnia, Bionô Roque das Chagas, Adenisar Delgado das Chagas, Heloisa Kreling da Silva   +3 more
doaj   +1 more source

Hetrombopag Added to Cyclosporine as the First‐Line Treatment for Patients With Non‐Severe Aplastic Anemia: A Phase 2 Multicenter Trial

American Journal of Hematology, Volume 101, Issue 3, Page 467-476, March 2026.
ABSTRACT Non‐severe aplastic anemia (NSAA) is a heterogeneous bone marrow failure syndrome with limited standardized treatment options. Cyclosporine A (CsA) monotherapy often yields suboptimal responses, highlighting an unmet clinical need for more effective therapies.
Lele Zhang, Ruonan Li, Qian Liang, Weiwang Li, Hong Pan, Zhen Gao, Liwei Fang, Jingyu Zhao, Xiao Yu, Zhexiang Kuang, Neng Nie, Jianping Li, Jinbo Huang, Xin Zhao, Meili Ge, Yizhou Zheng, Jun Li, Hong Zhang, Jun Shi   +18 more
wiley   +1 more source

Technical advances in flow cytometry-based diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria

Einstein (São Paulo)
Objective: To discuss the implementation of technical advances in laboratory diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria for validation of high-sensitivity flow cytometry protocols. Methods: A retrospective study based on analysis of
Rodolfo Patussi Correia, Laiz Cameirão Bento, Ana Carolina Apelle Bortolucci, Anderson Marega Alexandre, Andressa da Costa Vaz, Daniela Schimidell, Eduardo de Carvalho Pedro, Fabricio Simões Perin, Sonia Tsukasa Nozawa, Cláudio Ernesto Albers Mendes, Rodrigo de Souza Barroso, Nydia Strachman Bacal   +11 more
doaj   +1 more source

Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine

Haematologica, 2010
Background Clones of glycosylphosphatidylinositol-anchor protein-deficient cells are characteristic in paroxysmal nocturnal hemoglobinuria and are present in about 40–50% of patients with severe aplastic anemia.
Phillip Scheinberg, Michael Marte, Olga Nunez, Neal S. Young   +3 more
doaj   +1 more source

Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia–Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation

Frontiers in Medicine, 2020
Pregnancies in paroxysmal nocturnal hemoglobinuria (PNH) are associated with increased morbidity and mortality. Retrospective studies suggest that outcome has improved with the advent of the complement inhibitor eculizumab.
F. Alashkar, F. Saner, Colin Vance, U. Schmücker, Doerte Herich-Terhuerne, U. Dührsen, Angela Köninger, A. Röth   +7 more
semanticscholar   +1 more source